Noble Capital sets USD 1.40 target for Cosmos Health stock

Published on 10/27/2026 at 19:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 54.30 million in nine months, up 19.00 percent year over year. Cosmos Health stock costs EUR 0.21 on October 27, 2026.

Analyst target and growth

Noble Capital initiated coverage with an Outperform rating and a USD 1.40 target on October 26, 2026.
Preliminary nine-month revenue reached USD 54.30 million, up 19.00 percent year over year.
Cosmos Health stock costs EUR 0.21 at Lang & Schwarz on October 27, 2026 at 7:28 p.m. CEST.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health (US2214133058) received a new USD 1.40 price target from Noble Capital on October 26, 2026, when the firm initiated coverage with an Outperform rating. At Lang & Schwarz, the stock was trading at EUR 0.21 on October 27, 2026 at 7:28 p.m. CEST.

Noble Capital sets USD 1.40 target

According to Investing.com, Noble Capital analyst Michael Kupinski initiated coverage at Outperform and set the target at USD 1.40. The report also cited a gross profit margin of 10.27 percent and identified the shift toward proprietary healthcare products and pharmaceutical manufacturing as a profitability issue.

Revenue growth supplies the operating test

Cosmos Health reported preliminary nine-month revenue of USD 54.30 million, up 19.00 percent from the same period of 2025, in a shareholder letter dated October 20, 2026. StockTitan reported that management reaffirmed full-year 2026 revenue above USD 90.00 million.

The same letter said active U.S. subscriptions reached 8,940 on October 19, 2026, compared with 6,287 five days earlier. That is a 42.23 percent increase, calculated from the two subscription counts. Management also outlined a fiscal 2029 revenue objective of USD 200.60 million, alongside a gross-margin objective of 35.50 percent.

Nasdaq price and valuation frame

The Nasdaq quote was USD 0.24 on October 27, 2026 at 2:26 p.m. EDT. The 52-week Nasdaq range was USD 0.16 to USD 1.04, while the market capitalization was USD 24.0 million on the same date. The EUR 0.21 Lang & Schwarz quotation therefore remains the relevant German investor price in this report.

What does the target imply?

Noble Capital's USD 1.40 target stands beside a company reporting USD 54.30 million in preliminary nine-month revenue and 8,940 U.S. subscriptions. The figures point to a stock story built around execution of the stated revenue and margin objectives rather than a completed earnings turnaround.

Cosmos Health stock price

Cosmos Health was trading at EUR 0.21 at Lang & Schwarz on October 27, 2026 at 7:28 p.m. CEST. On the Nasdaq, the stock was at USD 0.24 on October 27, 2026 at 2:26 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of Cosmos Health stock.